Prospective genotype-guided drug selection and dosing in alcohol withdrawal syndrome complicated by seizures: a randomized clinical trial

OBJECTIVES: To determine whether prospective genotype-guided drug selection and dosing can reduce cumulative withdrawal severity and improve treatment tolerability in alcohol withdrawal syndrome (AWS) complicated by seizures. METHODS: In this single-center, parallel-group randomized clinical trial, 100 inpatients with AWS and seizures were allocated 1:1 to a genotype-guided prescribing strategy or control. All patients were genotyped on admission for CYP2D6*4, CYP2C19*2, CYP2C19*17, CYP3A4*1B, CYP3A5*3, and ABCB1 3435C>T. Intervention-group physicians received an individualized report with recommendations on benzodiazepine and anticonvulsant selection and starting dose; control-group physicians received a format-matched report without individualized recommendations. The primary outcome was area under the CIWA-Ar curve over 0-72 h, assessed by a blinded rater. RESULTS: AUC CIWA-Ar was 774.3 ± 175.9 vs. 903.6 ± 199.5 score-hours (mean difference -129.3; 95 % CI -204.0 to -54.6; p<0.001). Confirmed stabilization by 48 h occurred in 31/50 vs. 20/50 patients (log-rank p=0.020; Benjamini-Hochberg-adjusted p=0.051, not significant after multiplicity correction). UKU side-effect scores were lower on days 3 and 5 (both p<0.001), and excessive sedation occurred in 1/50 vs. 9/50 patients (p=0.016). Total benzodiazepine load was lower with genotype guidance (25.0 vs. 27.5 mg diazepam equivalents; p=0.016). The composite rate of clinically significant adverse events and the rates of delirium and unplanned treatment modification did not differ significantly. CONCLUSIONS: A prospective genotype-informed prescribing strategy was associated with lower cumulative withdrawal severity and less excessive sedation while using a lower benzodiazepine load. Because the intervention also changed anticonvulsant selection and drug concentrations were not measured, these findings support the clinical strategy as a whole rather than any single genotype-to-dose rule. Multicenter, prospectively registered trials with measured drug exposure are warranted.

Authors

Institutions

Publication Details

Journal
Drug Metabolism and Personalized Therapy
Published
2026-11-16
DOI
https://doi.org/10.1515/dmpt-2026-0060
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prospective genotype-guided drug selection and dosing in alcohol withdrawal syndrome complicated by seizures: a randomized clinical trial

A. V. Masyakin, Svetlana I. Sokolova, V A Ivanchenko, Valentin Yurievich Skryabin et al.
Drug Metabolism and Personalized Therapy
Pharmacogenetics and Drug Metabolism
article

Prospective genotype-guided drug selection and dosing in alcohol withdrawal syndrome complicated by seizures: a randomized clinical trial

A. V. Masyakin, Svetlana I. Sokolova, V A Ivanchenko, Valentin Yurievich Skryabin, Alla A. Matskevich
article en

Abstract

OBJECTIVES: To determine whether prospective genotype-guided drug selection and dosing can reduce cumulative withdrawal severity and improve treatment tolerability in alcohol withdrawal syndrome (AWS) complicated by seizures. METHODS: In this single-center, parallel-group randomized clinical trial, 100 inpatients with AWS and seizures were allocated 1:1 to a genotype-guided prescribing strategy or control. All patients were genotyped on admission for CYP2D6*4, CYP2C19*2, CYP2C19*17, CYP3A4*1B, CYP3A5*3, and ABCB1 3435C>T. Intervention-group physicians received an individualized report with recommendations on benzodiazepine and anticonvulsant selection and starting dose; control-group physicians received a format-matched report without individualized recommendations. The primary outcome was area under the CIWA-Ar curve over 0-72 h, assessed by a blinded rater. RESULTS: AUC CIWA-Ar was 774.3 ± 175.9 vs. 903.6 ± 199.5 score-hours (mean difference -129.3; 95 % CI -204.0 to -54.6; p<0.001). Confirmed stabilization by 48 h occurred in 31/50 vs. 20/50 patients (log-rank p=0.020; Benjamini-Hochberg-adjusted p=0.051, not significant after multiplicity correction). UKU side-effect scores were lower on days 3 and 5 (both p<0.001), and excessive sedation occurred in 1/50 vs. 9/50 patients (p=0.016). Total benzodiazepine load was lower with genotype guidance (25.0 vs. 27.5 mg diazepam equivalents; p=0.016). The composite rate of clinically significant adverse events and the rates of delirium and unplanned treatment modification did not differ significantly. CONCLUSIONS: A prospective genotype-informed prescribing strategy was associated with lower cumulative withdrawal severity and less excessive sedation while using a lower benzodiazepine load. Because the intervention also changed anticonvulsant selection and drug concentrations were not measured, these findings support the clinical strategy as a whole rather than any single genotype-to-dose rule. Multicenter, prospectively registered trials with measured drug exposure are warranted.

Drug Metabolism and Personalized Therapy
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare (RU)
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon